Wire · opportunities
FDA Approves Jemperli for Certain Patients With Locally Advanced Rectal Cancer
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 25 October 2026 · Fusion42 review
The FDA has granted accelerated approval to Jemperli (dostarlimab-gxly) for adults with stage II or III locally advanced rectal cancer exhibiting dMMR or MSI-H genetic features, offering an immunotherapy option that may allow some patients to avoid chemotherapy, radiation, and surgery.
This Wire brief sits within Fusion42's coverage of Biotech, and 15 sources have reported it between 19 Oct 2026 and 25 Oct 2026.
◆ ◆ The Wire takeaway
Jemperli’s FDA approval opens a new, less invasive treatment path that disrupts the standard chemo and surgery approach for rectal cancer. If you develop cancer therapies, this clearance shifts patient demand toward targeted immunotherapies that require strong genetic testing partnerships.
◆ Coverage
15 sources · first reported 19 Oct 2026 · latest 25 Oct 2026
◆ Related on Wire
◆ Topics